Volume 20.3 of the JMCM is now available. FEATURED ARTICLES INCLUDE: Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes. Clinical Advances in Atopic Dermatitis: Novel Therapies for Improved Patient Outcomes. Optimizing Outcomes in Advanced Non-Small Cell Lung Cancer: Integrating Novel Personalized Therapy into the Treatment Paradigm.
Current Issue Article:
Clinical Advances and Therapeutic Strategies
Because so many disease modifying therapies (DMT) have been approved for MS since the early 1990s, it can be difficult for managed care to keep up with all of them and to know how to manage use with each one. The decision process for clinicians to choose an agent is also difficult. Additionally, there are more therapies on the horizon.
Managed Care eNews
‘Dishing’ out a new test to improve breast cancer treatment
Excluding cancers of the skin, breast cancer is the most common cancer among women in the United States, accounting for 29 percent of newly diagnosed cancers. Breast cancer incidence and death rates generally increase with age, and 79 percent of new cases and 88 percent of breast cancer deaths occur in women 50 years of age and older.
Genomics Biotech and Emerging Medical Technologies
Massive study reveals schizophrenia’s genetic roots
Schizophrenia is a distressing disorder involving hallucinations, delusions, paranoia and agitation. It affects around one in 100 people in the U.S., with symptoms usually first appearing between the ages of 16 and 30. Its causes have long been debated, particularly regarding whether genetics plays a role. It is known to be highly heritable, but small sample sizes and other methodology hurdles stymied early attempts to discern a genetic link.
Prevention, Lifestyle & Wellness
The sneaky cause of your sugar cravings
Sugar can’t catch a break these days. With everyone from from HBO comedian John Oliver to Yahoo’s Global New Anchor Katie Couric bashing sugar’s vice-like grip on the modern diet, more and more people are deciding to ditch it. The problem? It’s really, really difficult.